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Abstract
Background: High tumour interstitial fluid pressure (IFP) has been adversely linked to poor drug uptake in patients, and
to treatment response following radiotherapy in cervix cancer patients. In this study we measured IFP values in a
selection of murine and xenograft models, spontaneously arising or transplanted either intramuscularly (i/m) or
orthotopically and analysed their relationship to tumour vascularity and metastatic spread.
Methods: KHT-C murine fibrosarcoma, ME180 and SiHa human cervix carcinoma were grown either intramuscularly
(i/m), sub-cutaneously (s/c) or orthotopically. Polyoma middle-T (MMTV-PyMT) transgenic spontaneous mammary
tumours were studied either as spontaneous tumours or following orthotopic or i/m transplantation. IFP was measured
in all tumours using the wick-in-needle method. Spontaneous metastasis formation in the lungs or lymph nodes was
assessed in all models. An immunohistochemical analysis of tumour hypoxia, vascular density, lymphatic vascular density
and proliferation was carried out in ME180 tumours grown both i/m and orthotopically. Blood flow was also assessed in
the ME180 model using high-frequency micro-ultrasound functional imaging.
Results: Tumour IFP was heterogeneous in all the models irrespective of growth site: KHT-C i/m: 2–42 mmHg, s/c:
1–14 mmHg, ME180: i/m 5–68 mmHg, cervix 4–21 mmHg, SiHa: i/m 20–56 mmHg, cervix 2–26 mmHg, MMTV-PyMT:
i/m: 13–45 mmHg, spontaneous 2–20 mmHg and transplanted 2–22 mmHg. Additionally, there was significant variation
between individual tumours growing in the same mouse, and there was no correlation between donor and recipient
tumour IFP values. Metastatic dissemination to the lungs or lymph nodes demonstrated no correlation with tumour IFP.
Tumour hypoxia, proliferation, and lymphatic or blood vessel density also showed no relationship with tumour IFP.
Speckle variance analysis of ultrasound images showed no differences in vascular perfusion between ME180 tumours
grown i/m versus orthotopically despite differences in IFP.
Conclusion: Our studies across a range of different tumour models showed substantial heterogeneity in tumour IFP,
suggesting differences in the vascular development and interstitial fluid dynamics in the individual tumours. The results
demonstrate a strong stochastic aspect to tumour IFP development, notably the variation apparent between different
tumours within the same animal and the lack of correlation between donor and recipient tumours.
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Background
Solid tumours show interstitial fluid pressures (IFP) that
are elevated above that of normal tissues. Tumour growth
and development is supported by both the pre-existing
host vasculature and by neovasculature generated through
the process of angiogenesis. Tumour angiogenesis gener-
ates abnormal vessels [1-3] that demonstrate several
anomalies including an incomplete or absent endothelial
cell layer and basement membrane which makes them
hyper-permeable [4]. These vessels exhibit a high resist-
ance to capillary blood flow and a low resistance to tran-
scapillary flow, resulting in a net efflux of fluid into the
surrounding interstitial space where a lack of functional
lymphatics allows it to accumulate, distending the elastic
extracellular matrix and increasing the interstitial pressure
[5,6]. An equilibrium is established where the capillary
and interstitial pressures are equivalent resulting in
reduced fluid movement through the interstitium [6]. In
addition, the tumour interstitium itself is thought to be
abnormal, comprising a dense network of collagen fibres,
as well as increased fibroblasts, macrophages and other
cells involved in inflammation, which further contribute
to elevated IFP values [3]. It is clear from these previous
studies that high IFP in tumours arises because of the
complex interplay between the abnormal vasculature and
the abnormal interstitium. However, the pathophysio-
logic mechanisms underlying widely varying IFP values in
human and experimental tumours of the same and differ-
ing types, and the influence of growth site and the host, is
less well understood.
Elevated tumour IFP plays a role in the pathophysiologi-
cal microenvironment that characterises solid tumours
contributing to disease progression and therapeutic resist-
ance [3,6-9]. The mechanisms involved remain to be fully
elucidated but several experimental animal studies have
shown an improved uptake of therapeutic agents in
response to a reduction in tumour IFP suggesting that
high tumour IFP acts as a barrier to drug delivery [10-17].
Furthermore, there are clinical data showing that tumour
IFP correlates with response to treatment [18,19], with
strong evidence for high IFP as an adverse prognostic indi-
cator in cervix cancer patients treated with radiotherapy
[7,9]. Patients in the latter study were significantly more
likely to develop distant recurrence if they presented with
a tumour IFP value above the group median (19 mmHg),
which suggests a role for IFP in metastatic spread. A rela-
tionship has also been observed between tumour IFP val-
ues and metastasis in experimental melanoma xenografts
[20].
These data, coupled with the breadth of data demonstrat-
ing elevated IFP in a wide range of human tumours
[7,18,19,21-25], designate high tumour IFP as an impor-
tant therapeutic problem. Further preclinical investigation
is needed to understand the mechanisms underlying the
adverse prognostic effect of high IFP and the implications
for treatment. However, little is known about the most
appropriate experimental model for these studies in rela-
tion to clinical tumour behaviour. To date most studies
have focused on tumour models grown sub-cutaneously
[13,26-28] although evidence suggests that orthotopic
models may be more clinically relevant [29,30]. Although
IFP has been measured in a variety of different tumour
models, to our knowledge no previous study has focussed
on the influence of tumour growth site on the develop-
ment of the pathophysiological tumour microenviron-
ment, or more specifically, tumour IFP. As such, the
purpose of this study was to assess IFP in a number of dif-
ferent murine (KHT-C) and xenograft (ME180, SiHa)
tumour models growing both ectopically and orthotopi-
cally and to examine features of the tumours (lymphatic
and blood vascular density, hypoxia, perfusion) that
might relate to the IFP levels and to disease progression.
The murine and xenograft models were selected on the
basis of previous studies within our lab [31,32] and the
polyoma middle-T (MMTV-PyMT) transgenic spontane-
ous mammary tumour model was included to allow com-
parison with the transplanted models [33]; IFP has only
previously been assessed in one other spontaneously aris-
ing tumour model [34]. The orthotopic human cervix can-
cer xenograft models were included because of the direct
relevance of this model to our clinical program [7,9]. IFP
was examined for each of the different tumour models
and growth sites and related to tumour size, metastatic
dissemination, tumour hypoxia, proliferation and vascu-
lar and lymphatic density.
Methods
Mice and tumour cell lines
Experiments were performed using MMTV-polyoma mid-
dle-T transgenic mice (MMTV-PyMT;[33]) bred in-house,
the previously described KHT-C murine fibrosarcoma cell
line [35] and the ME180 and SiHa human cervical carci-
noma cell lines stably transfected to constitutively express
the fluorescent marker DsRed [36]. All cell lines were
maintained on an alternative in vitro/in vivo growth cycle.
In vitro cells were maintained as monolayers in plastic tis-
sue culture flasks using α-MEM medium (Life Technolo-
gies, Inc., Burlington, Canada) supplemented with 10%
fetal bovine serum (Wisent, Quebec, Canada). The cervi-
cal carcinoma cell lines were maintained under G-418
selection (400 μg/ml). Cells between their 2nd and 5th in
vitro passage were removed from the flasks during expo-
nential growth using 0.05% trypsin for transplantation
into mice. KHT-C cells were transplanted into syngeneic
8–12 week old C3H/HeJ male mice (Jackson Laboratory,
Bar Harbour, ME). ME180 and SiHa cells were trans-
planted into 8–12 week old female CB-17/SCID mice
obtained from an in-house breeding program. PyMT cellsBMC Cancer 2008, 8:2 http://www.biomedcentral.com/1471-2407/8/2
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were transplanted into female FVB (wild-type, w.t.) or
SCID mice. Tumours were initiated either intramuscularly
(i/m) in the left gastrocnemius muscle, or sub-cutane-
ously (s/c) on the flank by injection of 2.5 × 105 or 5 × 105
cells respectively in a 50 μl volume of α-MEM media.
Tumours growing i/m were monitored by measuring the
external leg diameter of the mouse. Tumours growing s/c
were measured directly. Orthotopic cervical and mam-
mary gland tumours were initiated from donor tumours
using protocols described below. Animals were housed at
the Ontario Cancer Institute animal facility and had
access to food and water ad libitum. All experiments were
performed under protocols approved according to the reg-
ulations of the Canadian Council on Animal Care.
Orthotopic implantation in the cervix or mammary gland
The method for orthotopic implantation of tumour frag-
ments into the cervix has been described in detail previ-
ously [36]. In brief, donor tumours grown i/m were
excised under sterile conditions and small fragments
(1.5–2 mm in diameter) were sutured into the site of a
small incision in the uterus at the level of the cervix. Once
tumours were palpable, IFP measurements were taken and
tumours, lumbar lymph nodes and lungs were imaged/
removed for further analysis. Spontaneously arising
donor tumours in MMTV-PyMT transgenic mice were
excised under sterile conditions and divided into small
fragments of approximately 2 mm in diameter. A fine inci-
sion was made in the skin to expose the 4th mammary
gland. A small incision was made in the fat pad of the 4th
mammary glands and a tumour fragment was sutured in
place using a single 8-0 silk suture. The skin was closed
using stainless steel wound clips. The left and right 4th
mammary glands were implanted with a donor tumour
fragment from either the same or a different donor
tumour (Additional File 2). This allowed the effect of
donor tumour variability on the subsequent development
of the recipient tumour microenvironment to be assessed
without the confounding factor of inter-animal variabil-
ity. All surgical procedures were carried out under anaes-
thesia (2% isofluorane). Buprenorphine (0.1 mg/kg) was
administered s/c following surgery to alleviate pain.
Tumour growth was monitored using callipers to measure
the width and length of the tumour; once a size of 50–80
mm2 was attained IFP measurements were initiated. Mice
were sacrificed once a tumour reached a size of 200–250
mm2. Half of each tumour was fixed in 10% neutral buff-
ered formalin and half was snap frozen in OCT for histo-
logical analyses. The lungs were excised for examination
of metastases.
Pressure treatment in vitro
KHT-C tumour cells were exposed to elevated pressure (20
mmHg) for various times in vitro in 10 cm tissue culture
dishes seeded with a sub-confluent cell monolayer in a
modular incubator chamber (Billups-Rothenberg, Del
Mar, Canada). Pressure levels used were based on the
average IFP values apparent when grown i/m. Pressure
was controlled through adjustments of a dual scale low
pressure gauge (0–15 KPa; Cole Parmer, Quebec, Canada)
on the outlet port. Control cells were gassed using the
same system, but without the addition of a pressure gauge
on the outlet port, allowing the gas to flush through freely
at atmospheric pressure. The metastatic potential of pres-
sure treated tumour cells was assessed using an experi-
mental lung metastases assay [37].
IFP measurements
Interstitial fluid pressure was measured using a wick-in-
needle technique [38]. Measurements were made using a
23-gauge needle with side port connected to a pressure
transducer (Model P23XL, Viggo-Spectramed, Oxnard,
CA) and an electronic data acquisition and recording sys-
tem (Model MP100, World Precision Instruments, Sara-
sota, FL) through 470 mm of PE20 polyethylene tubing
(Becton Dickinson, Franklin Lakes, NJ, USA). A "wick"
was placed in the distal portion of the needle, and the
entire system was flushed with a heparin sulphate/saline
solution (1:10) [39]. IFP measurements were taken at
three to four different locations in the tumour, and the
mean value of these readings was taken to represent the
tumour IFP.
Assessment of macroscopic and microscopic metastases
Following sacrifice of tumour bearing animals, the lungs
were removed and fixed overnight in Bouin's solution
(BDH Inc., Toronto, Canada). A dissecting microscope
was used to count the number of visible metastases in
each of the five lobes and the total number of lesions
counted per lung reported (KHT-C and MMTV-PyMT). In
the case of too many metastatic lesions to count, the wet
weight of the lungs was taken as representative of meta-
static burden. For the orthotopic ME180 tumours that had
been transfected to express DsRed, lymph node metas-
tases were visualised by fluorescence and counted as pre-
viously described [36].
Microscopic lung metastases were detected immunohisto-
chemically (ME180 and SiHa) following fixation of lungs
in Bouin's solution (BDH Inc., Toronto, Canada). All five
lobes were paraffin embedded and four 4 μm sections 150
μm apart were cut from each lobe. The number of visible
micro-metastases in each of the five lobes was then
counted using a light microscope. Two or more clumped
tumour cells were scored as a lesion. Micro-metastases are
reported as the total number of lesions counted per lung.BMC Cancer 2008, 8:2 http://www.biomedcentral.com/1471-2407/8/2
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Histological Analyses
Analyses were carried out using immunohistochemistry
for tumour hypoxia (EF5), vascular density (CD31), lym-
phatic vessel density (LYVE-1), and proliferation (Ki67).
Tumour bearing animals were injected with the hypoxia
marker EF5 [2-(2-nitro-1H-imidazole-1-yl)-N-(2,2,3,3,3-
pentafluoropropyl) acetamide]; obtained from Dr. Cam-
eron Koch, University of Pennsylvania, at 10 mg/kg 2.5 h
prior to tumour excision. Once excised, half of the tumour
was fixed in 10% neutral buffered formalin, and the
remaining half placed in optimal cutting temperature
(OCT) embedding medium (Tissue-Tek, Sakura, USA),
and snap frozen in liquid nitrogen. Paraffin-embedded
tissue was used for all markers with the exception of
CD31.
For each marker, two sections were cut 100 μm apart due
to intra-tumoural heterogeneity (4 μm sections for paraf-
fin-embedded tissue, 5 μm sections for frozen tissue). The
slides were then processed according to standard immu-
nohistochemical protocols. The primary antibodies used
were: for EF5, the biotinylated antibody ELK3-51 (1/500;
a gift from Dr. Cameron Koch, University of Pennsylva-
nia); for CD31, the rat anti-mouse CD31, clone MEC 13.3
(1/500; Pharmingen, Canada); for Ki67, mouse anti-
human Ki67 clone MIB-1 (1/100; DAKO, Canada); for
LYVE-1, rabbit anti-mouse LYVE-1 (1/200 Abcam, Can-
ada). For all markers, apart from EF5, primary incubation
was followed by a 30 minute incubation with a bioti-
nylated secondary (Vector Labs, Canada) and horseradish
peroxidase conjugated ultrastreptavidin labelling reagent
(ID labs, Canada). Nova Red (Vector) with Mayer's hema-
toxylin counterstain was used for chromogenic detection.
The stained sections were analysed using the Aperio imag-
ing system (Aperio Technologies, California). Entire sec-
tions were scanned using the ScanScope CS and the total
area of positive staining quantified using a positive pixel
algorithm designed for brown/blue immunohistochemi-
cal stains. The same settings were used for each stain
across all images, and the area of positive staining was cal-
culated by dividing the total number of positive pixels
(weak, medium and strong staining) by the total number
of pixels in the image (positive + negative pixels) to yield
the overall percentage of positive pixels. To assess intra-
tumour heterogeneity for each stain, 10 (CD31) or 20
(EF5, Ki67 and LYVE1) high-magnification (20×) fields
were randomly selected from each tumour section and
analysed independently using the same methodology.
Blood flow detection using high-frequency micro-
ultrasound functional imaging
Real-time ultrasound biomicroscopic imaging of anaes-
thetised (2% isofluorane) mice was carried out using
speckle variance analysis of high frequency ultrasound
(Vevo660, VisualSonics, Inc., Toronto, ON, Canada)
images as previously described [40]. The ultrasound trans-
ducer transmits at a central frequency of 40 MHz with a
focal length of 6 mm. The lateral and axial resolutions
were 68 and 38 μm, respectively. Ultrasound gel (Aqua-
sonic 100, Parker Laboratories, Fairfield, NJ) was used as
a coupling agent on the skin. A minimum of five bright-
ness mode (B mode) two-dimensional image planes were
acquired per tumour, each with cineloops of 300 frames
at a frame rate of 17/s. Speckle pattern and intensity dur-
ing real-time B mode imaging of stationary tissue remain
constant, and the temporal variance of speckle intensity
increases with tissue motion. A speckle-variance flow-
processing algorithm devised by Yang [41] was used to
calculate changes in speckle intensity between sequential
frames as an indication of functional blood flow [40].
This technique gives a relative indication of the number of
perfused vessels in each tissue plane, and has been vali-
dated previously against perfusion assessed using injec-
tion of Hoechst 33342 [40]. Each of the 5 B mode image
planes were analysed for 3 i/m and 6 cervix ME180
tumours.
Statistical Analysis
Experiments with three or more groups were analysed for
statistical significance using the Kruskal-Wallis statistic,
and individual comparisons within these groups were car-
ried out using Dunn's test. Experiments with two groups
were analysed for statistical significance using the Mann-
Whitney statistical test. Correlation was assessed using the
correlation coefficient derived from linear-regression
analysis.
Results
IFP varies between tumours of both the same and different 
origins
Tumour IFP was measured in a number of different
murine and xenograft tumour models grown both ectopi-
cally and orthotopically. Substantial inter-tumour
(between individual tumours) heterogeneity was appar-
ent for all tumour models irrespective of site (Figure 1 and
Additional File 1). Interestingly, ME180 and SiHa
tumours grown orthotopically in the cervix or MMTV-
PyMT tumours in the mammary fat pad consistently dem-
onstrated IFP values lower than those grown i/m (p <
0.05). Similarly, KHT-C growing s/c had lower IFP values
as compared to tumours growing in the i/m site, demon-
strating that in these models tumour IFP is higher when
growing intra-muscularly. The least inter-tumoural varia-
bility in the i/m site was seen in the KHT-C tumour model.
In the cervical carcinoma xenograft models growing
orthotopically, IFP was significantly higher in the SiHa
model as compared to the ME180 model.BMC Cancer 2008, 8:2 http://www.biomedcentral.com/1471-2407/8/2
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The inter-tumour heterogeneity apparent in tumours
growing at the same site in different animals was also
observed in individual tumours growing within the same
animal (Figure 2). Multiple spontaneously arising
tumours in the mammary glands of an individual trans-
genic MMTV-PyMT mouse demonstrated a wide range of
IFP values (5–20 mmHg, Figure 2A). Similarly, when
mammary tumours derived from the same donors were
directly transplanted orthotopically into both the left and
right 4th mammary gland of recipient mice, the subse-
quent tumours showed divergent IFP values (Figure 2B).
However, the range of IFP values seen in spontaneously
arising mammary gland tumours was comparable to the
range of values seen in tumours transplanted orthotopi-
cally (Additional File 1).
To investigate whether transplant into different host mice
impacted IFP levels, mammary gland tumours were trans-
planted into the mammary glands of either SCID
(immune deficient) or FVB (syngeneic) recipient mice.
Tumour IFP values were found to be similar irrespective of
the mouse background (Figure 2E), suggesting that the
tumour cell genetics may have more impact on the range
of IFP values for a specific tumour type than the host
genetics in experimental models.
Donor tumour IFP is not predictive of recipient tumour IFP
To ascertain whether the pre-existing tumour microenvi-
ronment and molecular interactions can impact on
tumour development, donor tumour IFP values were
measured prior to transplantation into the relevant ortho-
topic site in the ME180, SiHa and MMTV-PyMT tumours.
IFP values in the transplanted tumours showed no corre-
lation with those in the donor tumours (Figure 2C).
Although the donor ME180 and SiHa tumours were
grown i/m prior to orthotropic transplantation, which
might have confounded this comparison, the donor PyMT
tumours were grown orthotopically in the mammary fat
pad. Furthermore, the mice bearing two MMTV-PyMT
orthotopically transplanted mammary tumours showed
disparities in tumour IFP measurements irrespective of
whether they were initiated from different or the same
donors (Additional File 2 & Figure 2D). All these results
are consistent with no relationship between IFP values in
the donor and transplanted tumour irrespective of trans-
plantation site.
Correlation between tumour size and IFP is tumour 
specific
Previous studies have noted a tumour specific correlation
between tumour size and IFP [7,26,28,42-45]. Although,
the mean tumour size at the time of the IFP measurements
was similar for all of the tumour models at all sites (Figure
3A), the use of tumours with different sizes permitted an
analysis of the relationship between tumour size and IFP
in a subset of tumours within most of the models (Figure
3B–F). A significant correlation between tumour size and
IFP was seen only for KHT-C tumours growing i/m (p ≤
0.02; Figure 3B).
Comparison of IFP values between different growth sites and different models Figure 1
Comparison of IFP values between different growth sites and different models. Mean IFP is shown for each tumour 
line growing orthotopically and ectopically; KHT-C i/m (n = 104) and s/c (n = 12) tumours, MMTV-PyMT i/m (n = 15), trans-
genic spontaneous mammary gland (n = 27), and transplanted orthotopic mammary gland (n = 62) tumours, ME180 i/m (n = 
26) and orthotopic cervix (n = 28) tumours, SiHa i/m (n = 9) and orthotopic cervix (n = 10) tumours. The error bars represent 
the standard error of the mean. An asterix indicates that a group is significantly (p ≤ 0.05) different to the other groups.
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High tumour IFP does not correlate with increased 
metastatic efficiency
Cervical carcinoma patients with a high tumour IFP are at
increased risk of distant recurrence after treatment with
radiotherapy [7,9]. Furthermore, Rofstad et al (2002) [20]
showed experimentally that oxic melanoma tumours with
a high IFP showed a significantly increased metastatic
ability. However, the relationship between tumour IFP
and metastatic disease has not been widely studied. Con-
sequently, we examined metastases formation in each of
the tumour models (apart from the SiHa model which did
not metastasise from either the orthotopic or i/m site) but
Inter-tumour variability within the same animal Figure 2
Inter-tumour variability within the same animal. A) The mean IFP value (mmHg) for each individual mammary gland 
tumour arising in four different MMTV-PyMT transgenic mice is shown. The bar represents the median IFP value (mmHg) for 
each mouse. There was substantial variation between different tumours within the same mouse. B) The mean IFP value 
(mmHg) for each of two orthotopic MMTV-PyMT tumours, one transplanted into the left and one into the right 4th mammary 
gland, is shown. The tumours from the same donor animal are connected by a solid line. Again, there was obvious variation in 
the IFP values of different tumours growing within the same animal. C) Recipient tumour IFP (mmHg; y-axis) plotted as a func-
tion of the mean donor IFP (mmHg; x-axis). The line of identity is shown. There was no correlation between donor and recip-
ient IFP. D) The difference in the mean IFP values of two different tumours growing in the left and the right mammary glands is 
shown, grouped according to whether the two tumours were initiated from the same or different donor tumours. The median 
IFP for each group is indicated; there was no significant difference (Mann Whitney test p ≥ 0.05). E) The mean tumour IFP is 
shown for each individual MMTV-PyMT mammary gland tumour transplanted into either SCID or FVB mouse backgrounds. 
The bar indicates the median IFP values. The IFP values were comparable for both mouse backgrounds.
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
 
￿
 
￿
!
￿
!
￿
"
#
$
%
#
&
’
(
)
*
$
$
+
,
-
.
/
0
1
2
3
4
5
0
5
1
5
2
6
7
8
6
7
9
9
9
7
:
9
7
;
9
7
8
9
7
9
<
=
>
?
=
@
A
B
C
D
>
>
E
F
G
H
I
J
K
L
M
L
L
M
N
O
K
P
L
Q
P
N
R
S
T
U
K
L
M
L
L
M
N
O
K
P
L
Q
P
N
V
/
W
0
2
0
X
0
3
0
A
B
C
D
>
>
E
F
G
Y
Z
[
\
]
^
_
‘
a
b
c
Y
d
e
/
f
/
g
h
i
j
k
l
m
n
o
n
p
o
q
q
o
n
r
o
q
s
n
o
n
s
p
o
q
t
u
v
w
u
x
y
z
{
|
v
v
}
~
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
0
5
0
1
0
0
X
5
0
5
X
1
0
1
X
W
0
￿
￿
￿
￿
￿
￿
￿
￿
￿
A
￿
￿
¡
￿
¢
£
⁄
¥
ƒ
§
§
¤
'
“
«
/BMC Cancer 2008, 8:2 http://www.biomedcentral.com/1471-2407/8/2
Page 7 of 14
(page number not for citation purposes)
Tumour size and IFP values Figure 3
Tumour size and IFP values. Graph A shows the mean tumour size at the time of IFP measurement for each model. Error 
bars represent standard error of the mean, and a significant difference is indicated by an asterix. There were no significant dif-
ferences in mean tumour size between models, with the exception of SiHa tumours growing in the cervix, which were signifi-
cantly larger than SiHa or KHT-C tumours growing i/m. Graphs B-F show the mean tumour IFP (mmHg, y-axis) of individual 
tumours plotted against the tumour size (g or mm2; x-axis). The R2 value is shown on each graph. B) KHT-i/m tumours, C) 
ME180 cervix tumours, D) SiHa cervix tumours, E) MMTV-PyMT transplanted orthotopic mammary gland tumours, F) 
MMTV-PyMT i/m tumours. There was a correlation between tumour size and IFP only in the KHT-C tumour model growing i/
m.
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found no correlation between a high tumour IFP and
enhanced metastatic potential (Figure 4A–G). For the
MMTV-PyMT model growing orthotopically or in the
transgenic animals, due to the presence of multiple
tumours with divergent IFP values in each animal, metas-
tases data are plotted according to the mean IFP value of
all the tumours within that animal.
Elevated tumour IFP is a consequence of complex patho-
physiologic interactions between the tumour vasculature
and the interstitium. Factors that influence IFP may also
influence other aspects of the tumour microenvironment,
including the development of hypoxia, which has previ-
ously been shown to enhance metastatic ability
[31,32,37,46-50] and could potentially confound the in
vivo analysis. Thus, in an attempt to elucidate the role of
elevated pressure per se, KHT-C tumour cells were also
grown under conditions of high pressure in vitro prior to
analysis of metastatic ability with an experimental metas-
tases assay in vivo. No evidence for a correlation between
exposure to elevated pressure and metastatic ability was
observed for the KHT-C tumour line (Additional File 3),
consistent with the spontaneous metastases data. The
other models were not investigated for this study, as they
do not form a sufficient number of lung metastases fol-
lowing i/v injection.
Model-specific differences in vascular density, tumour 
hypoxia and tumour proliferation in relation to tumour IFP
Differences in IFP from one tumour to the next may be
due to differences in the underlying tumour microvascu-
lar and lymphatic architecture. Consequently, an immu-
nohistochemical analysis was carried out using CD31
(vascular density) and LYVE-1 (lymphatic vessel density)
staining. In addition, proliferation was assessed using the
proliferation marker Ki67, as it has been suggested that
genes involved in cellular proliferation may be upregu-
lated in tumours with higher IFP values [51,52]. Tumour
hypoxia, a common feature of the pathophysiological
tumour microenvironment, was also examined using the
hypoxic marker EF5.
The ME180 model growing either i/m or orthotopically
was chosen for detailed characterisation, because this
model is the most appropriate for an analysis of meta-
static progression to the regional lymph nodes, the most
clinically relevant metastatic site, as well as the lungs. In
addition, previous studies have demonstrated that expo-
sure of ME180 orthotopic tumour bearing mice to cyclic
hypoxia enhances metastatic spread to the lymph nodes
[31]. Two tumour sections taken 100 μm apart showed a
good agreement for all of the markers (Figure 5E). The
analysis of these sections indicated no significant differ-
ences in tumour hypoxia, proliferation, vascular area or
lymphatic vascular area between ME180 tumours growing
in the i/m site versus orthotopically. Furthermore, there
were no significant differences between tumours with a
high (above median) or low (below median) IFP for
either site (Figure 5F–J). To assess intra-tumour variabil-
ity, a random high-power field (20×) analysis was carried
out for each parameter. The average values for all fields
were analogous to the values obtained through whole
image analysis. There were no significant differences
between the tumours growing i/m versus orthotopically
(Additional File 4A). Furthermore, although there was
substantial heterogeneity between fields within any one
tumour section, the degree of intra-tumour heterogeneity
was not related to tumour IFP (Additional File 4B-I).
Similar, more limited, analyses were carried out in the
MMTV-PyMT model growing in different sites. There were
no significant differences in lymphatic or blood vascular
area or hypoxic fraction for MMTV-PyMT across the differ-
ent sites. Proliferation was seen to vary; however, there
was no relationship to tumour IFP (Additional File 5A-D).
Imaging of perfusion in ME180 tumours growing 
orthotopically or in the i/m site
High-frequency micro-ultrasound functional imaging and
speckle variance analysis were used to detect blood flow
and examine perfusion in ME180 tumours growing both
orthotopically and i/m. Composite images of positive
speckle signal associated with blood flow, overlaid on top
of the greyscale B mode ultrasound anatomical image of
the tumour, are shown for each site in Figures 6A &6B.
Analysis of cineloops from five randomly selected image
planes in each tumour indicated that the mean perfused
area for each tumour did not differ significantly according
to site (Figure 6C).
Discussion
There is increasing interest in the adverse effects of ele-
vated tumour IFP on drug delivery and treatment
response. The aim of this study was to characterise this rel-
atively unexplored parameter of the pathophysiological
tumour microenvironment in a range of tumour models
growing in different sites as a foundation for future exper-
iments and to explore various phenotypic properties such
as blood and lymphatic vascular density and tumour
hypoxia that may impact on the development of tumour
IFP. Systematic differences in tumour IFP as a function of
both tumour type and implantation site were observed,
consistent with an effect of predetermined genetic factors
and interactions between the tumour and host microenvi-
ronments in regulating IFP. However, this explained only
a portion of the total observed variability in IFP, possibly
reflecting stochastic development and remodelling of the
tumour vasculature.BMC Cancer 2008, 8:2 http://www.biomedcentral.com/1471-2407/8/2
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Metastases presentation as a function of tumour IFP Figure 4
Metastases presentation as a function of tumour IFP. The number of macro- or microscopic lung lesions or involved 
lymph nodes counted is shown for different tumour models. The data is presented as number of metastastic lesions/involved 
lymph nodes (y-axis) of individual tumours plotted against mean tumour IFP (mmHg; x-axis). The R2 value is shown on each 
graph. There was no significant correlation for any of the models. A) KHT-C i/m, B) KHT-C s/c tumours, C) MMTV-PyMT i/
m tumours,D) MMTV-PyMT MG tumours (total mean IFP shown), E) ME180 i/m tumours, F) ME180 cervix tumours (lung 
metastases), G) ME180 cervix tumours (lymph node metastases).
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Immunohistochemical analyses of tumour hypoxia, proliferation and vascular area Figure 5
Immunohistochemical analyses of tumour hypoxia, proliferation and vascular area. A representative image for 
each marker is shown (10× magnification; ME180 tumour growing i/m) A) EF-5,B) Ki67,C) CD31,D) LYVE-1.E) Sections were 
taken on two levels, 100 μm apart to assess intra-tumoural heterogeneity. The correlations between levels 1 (L1) and 2 (L2) 
are shown. Each point represents an individual tumour (includes data from PyMT tumours; see Additional File 5), and the leg-
end indicates the tumour model and site of growth. The line of identity is shown. Quantitative analysis of two sections from 
each tumour; bars represent the median percentage of positive staining [(positive pixels/total number of pixels (positive + neg-
ative)) × 100] and error bars show the range. F) Each marker according to whether the tumour was grown in the cervix (n = 
9) or i/m (n = 9). G-J) Each marker in both growth sites split according to whether the tumour IFP was above (high; n = 5) or 
below (low; n = 5) the median IFP; F) EF-5, G) Ki67, H) CD31 and I) LYVE-1.
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IFP levels in individual tumours are influenced primarily
by three fundamental pathophysiologic parameters: the
trans-capillary and interstitial hydraulic conductivities
and the capillary pressure [5,53,54]. In general, tumours
are characterized by abnormal, highly permeable vessels
and a relatively impermeable interstitium [6]. Fluid that
leaks from the vessels accumulates in the interstitium and
causes the pressure to rise. However, there is probably
wide variability in each of these parameters among indi-
vidual tumours, which contributes to heterogeneity in IFP
values. In tumours where the trans-capillary conductivity
is substantially less than interstitial conductivity, the IFP is
low and much less than the capillary pressure. At the other
extreme, where trans-capillary conductivity is high and
interstitial conductivity is low, IFP becomes almost equal
to the capillary pressure. This is thought to occur in many
pre-clinical tumour models [55] and possibly also in
human malignancies. Tumours with high flow resistance
due to unregulated angiogenesis, high cell density or
tumour growth in a confined space with vascular com-
pression would be expected to have both high capillary
and high interstitial pressure values. The important role of
the vasculature in determining IFP is supported by studies
of anti-vascular drugs that have shown reductions in
tumour IFP with vascular regression or normalisation
[11,39,56].
In our study, tumours grown orthotopically consistently
demonstrated IFP values lower than those grown in the i/
m ectopic site (Figure 1). This is in contrast to results
described by Brekken et al. (2000) [30] who demon-
strated higher IFP values in a human osteosarcoma line
grown orthotopically as compared to s/c. This difference
highlights the interaction between the tumour and the
surrounding normal tissue and its influence on IFP. For
example, tumours growing in bone would be expected to
have high blood flow resistance and high capillary pres-
sure because of progressive vascular compression as the
cell mass increases in a confined, noncompliant space. In
addition, there may be fewer normal lymphatic vessels in
close proximity to the tumour, effectively reducing inter-
stitial conductivity and driving up IFP until it equals the
capillary pressure. We also demonstrated that tumours
grown i/m have higher IFP values than those grown s/c, in
the cervix, or in the mammary fat pads, probably reflect-
ing similar pathophysiologic mechanisms. Overall, our
results suggest that site-specific differences in vascular
development and remodelling, and consequently flow
resistance and pressure, as well as site-driven differences
in the extracellular matrix, lead to systematic differences
in IFP values. We speculate that heterogeneity in IFP val-
ues among individual tumours of the same type growing
at the same site reflect the stochastic nature of unregulated
angiogenesis in tumours and the random nature of the
resultant vasculature.
In further support of these concepts, the MMTV-PyMT
transgenic mammary gland tumours growing orthotopi-
cally in the mammary fat pad showed IFP values that were
comparable to the spontaneously arising tumours. Also,
there were no differences when tumours were trans-
planted into FVB or SCID hosts. However, when grown i/
m, the IFP in the MMTV-PYMT tumours was significantly
increased. Since the data showed no relationship between
donor IFP and recipient IFP this suggests a site-specific
effect. Similar findings in the cervical tumour models sug-
gest individual tumour development irrespective of any
tumour microenvironment-induced molecular interac-
tions that may have existed in the original donor tumour.
It is interesting that although the tumour vasculature
plays a vital role in the development of both tumour IFP
and tumour hypoxia, there was no correlation between
these two parameters, an effect that has also been
observed both experimentally [26,57] and in the clinic
[7]. In addition, there was no relationship between vascu-
lar area and IFP, with similar values being observed in all
High-frequency micro-ultrasound functional imaging Figure 6
High-frequency micro-ultrasound functional imag-
ing. Representative composite images of ME180 tumours 
growing A) in the cervix and B) i/m are shown. Positive 
speckle signal associated with blood flow is overlaid on top of 
the greyscale B mode ultrasound image. C) The tumour 
mean (from the 5 frames) percentage positive signal (blood 
flow) for each tumour are shown for ME180 tumours grow-
ing either in the cervix or i/m. Each point represents an indi-
vidual tumour. The median is indicated on the graph.
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models. Furthermore, in our high frequency ultrasound
speckle variance analysis of blood flow in a small number
of tumours, vascular perfusion was also comparable
between ME180 tumours growing in the cervix versus i/m.
There is evidence in the literature that high primary
tumour IFP is associated with a higher incidence of meta-
static disease [7,20,23], although Rofstad et al. (2002)
suggest that it is neither necessary nor sufficient. In the
present study we found no indication of a relationship
between high tumour IFP and metastatic disease in any of
the models in any of the sites. A controlled in vitro exper-
iment designed to test the influence of pressure on the
metastatic ability of cancer cells without the potentially
confounding influence of other microenvironmental fac-
tors also showed no effect. These data are consistent with
clinical data where, although a high pre-treatment IFP in
cervical carcinoma patients was associated with a high risk
of distant metastases following treatment with radiother-
apy, there was no correlation between IFP and metastatic
disease at the time of diagnosis [7]. It is possible that
tumour IFP may be more a marker of treatment response
than have a direct causative effect on metastatic spread.
Conclusion
The data presented provide, for the first time, a specific
analysis of tumour IFP across a selection of different
tumour models encompassing human, murine trans-
planted and spontaneous tumours, growing in different
sites. We demonstrate inherent inter-tumour heterogene-
ity, and a lack of correlation both between tumour donors
and recipients and between different tumours growing
within the same animal. Our findings indicate systematic
differences in IFP as a function of tumour type consistent
with predetermined inherent genetic differences that
influence vascular development and the composition and
organisation of the interstitium. There are also systematic
differences as a function of growth site, presumably
reflecting the interaction between the tumour and the sur-
rounding host normal tissue. Nevertheless, the heteroge-
neity of IFP in individual tumours growing under similar
conditions suggests that IFP is probably influenced to a
large extent by the stochastic nature of vascular develop-
ment and remodelling during tumour growth. In this con-
text it is surprising that an analysis of various phenotypic
parameters failed to show any correlation between IFP
and tumour hypoxia, tumour proliferation, blood or lym-
phatic vascular density. Whether the lack of correlation in
these parameters is indicative of no involvement in the
development of tumour IFP remains uncertain, however,
since the parameters are interdependent and may act
together to elevate IFP. It is clear that factors influencing
tumour IFP are complex and that further study is required
to reveal the mechanisms that elevate IFP and its impor-
tance in therapeutic response either as a stand-alone factor
or in combination with other factors.
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